Victoria Socha

DocwireNews

Among patients with autosomal dominant polycystic kidney disease (ADPKD), the expected rate of decline in estimated glomerular filtration rate (eGFR) is calculated using the 2015 ADPKD&nbsp; risk classification system developed by Irazabal et al. The system is based on patient height-adjusted kidney volume (htTKV) and age. Patients with typical image findings on MRI (class 1) can be categorized for anticipated slope of eGFR decline from slow progressors (subclass 1A) through rapid progressors (subclass 1E).For most, but not all patients, subclass assignment remains stable over time, dependent on htTKV growth. Neera K. Dahl, MD, PhD, and colleagues performed an analysis of data from the TEMPO 3:4 trial to examine the effects of tolvaptan on ADPKD risk subclass over time. Results of the analysis were reported during a poster session at the American Society of Nephrology Kidney Week 2022 in a poster titled Tolvaptan Modifies Patient Risk Class Distribution Over Time in Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Data From the TEMPO 3:4 Trial.The post hoc analysis was designed to compare changes in risk subclass between patients randomized to tolvaptan or placebo. Baseline MRI and age were used to identify patients in subclasses 1B to 1E. The Cochran-Mantel-Haenszel mean score statistic was used compare the proportions of participants (completers only) in both treatment arms in each baseline subclass who shifted to a different subclass over 36 months.Most of the participants in the TEMPO 3:4 placebo arm remained in their baseline subclass; some progressed to a higher risk subclass and a smaller proportion dropped into a lower risk subclass. In the tolvaptan arm, the proportion of participants who progressed to a higher risk subclass was smaller than the proportion of participants who dropped into a lower risk subclass.In baseline subclasses 1C and 1D, participants in the placebo arm were statistically more likely to progress to a higher risk subclass than those in the tolvaptan arm subclasses 1C (P&lt;.001) and 1D (P=.0087).In summary, the researchers said, &ldquo;Reduction of htTKV growth by tolvaptan in ADPKD improved the population risk profile during the 3-year period of treatment with tolvaptan or placebo.&rdquo;Source: Dahl NK, Chebib FT, Rahbari-Oskoui FF et al. Tolvaptan modified patient risk class distribution over time in autosomal dominant polycystic kidney disease (ADPJD): an analysis of data from the TEMPO 3:4 trial. Th-PO413. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 3, 2022; Orlando, Florida. Funding was provided by Otsuka Pharmaceutical Development &amp; Commercialization Inc.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Risk Profile Improved With Tolvaptan for ADPKD

ADPKD

Among patients with autosomal dominant polycystic kidney disease (ADPKD), the expected rate of decline in estimated glomerular filtration rate (eGFR) is calculated using the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe